

Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum hypertension in the first 6 weeks after delivery.

I

C

© ESC 2025

ACE-I, angiotensin-converting enzyme inhibitor; ACHD, congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; ALARA, as low as reasonably achievable; aPTT, activated partial thromboplastin time; APO, adverse pregnancy outcome; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, acetylsalicylic acid; AV, atrioventricular; BAV, bicuspid aortic valve; BP, blood pressure; CMP, cardiomyopathy; CMR, cardiovascular magnetic resonance; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CT, computed tomography; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DCM, dilated cardiomyopathy; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ECG, electrocardiogram; EF, ejection fraction; FAT, focal atrial tachycardia; GDM, gestational diabetes mellitus; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HTAD, heritable thoracic aortic disease; ICD, implantable cardioverter defibrillator; INR, international normalized ratio; i.v., intravenous; LDS, Loeys–Dietz syndrome; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MFS, Marfan syndrome; MHV, mechanical heart valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; NYHA, New York Heart Association; oGTT, oral glucose tolerance test; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PH, pulmonary hypertension; P/LP, pathogenic/likely pathogenic; PPCM, peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; SGLT2, sodium–glucose co-transporter-2; SVT, supraventricular tachycardia; TGA, transposition of the great arteries; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; UFH, unfractionated heparin; VKA, vitamin K antagonist; VT, ventricular tachycardia; VTE, venous thromboembolism; WPW, Wolff–Parkinson–White.

^aClass of recommendation.

^bLevel of evidence.

19. Author information

Author/Task Force Member Affiliations: **Nina Eide Hasselberg**, Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; **Michèle de Hosson**, Cardiology, Ghent University Hospital, Ghent, Belgium; **Margarita Brida**, Department of Rehabilitation and Sports Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia, and Adult Congenital Heart Disease Centre, Royal Brompton and Harefield Trust and Imperial College, London, United Kingdom; **Silvia Castelletti**, Cardiology Department, IRCCS Istituto Auxologico Italiano, Milan, Italy; **Matthew Cauldwell**, Obstetrics, St George's Hospital, London, United Kingdom; **Elisabetta Cerbai**, Department of Neurosciences, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, and European Laboratory for Non-Linear Spectroscopy, LENS, Sesto Fiorentino, Italy; **Lia Crotti**, Department of Cardiology, Cardiomyopathy Unit, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, IRCCS, Istituto Auxologico Italiano, Milan, Italy, and Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; **Natasja M.S. de Groot**, Unit Translational Electrophysiology, Department of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands; **Mette-Elise Estensen**, Department of Cardiology, Oslo University Hospital, Oslo, Norway; **Eva S. Goossens**, Centre for Research and Innovation in Care, Department of Nursing and Midwifery, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium, and Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium, and Department of Patient Care, Antwerp University Hospital, UZA, Antwerp; **Bernhard Haring**, Klinik für Innere Medizin III, Saarland University, Homburg, Germany; **Donata Kurpas**, Division of Research Methodology, Department of Nursing, Wrocław Medical University, Wrocław, Poland; **Carmel M. McEniery**, Department of Medicine, University of Cambridge, Cambridge, United Kingdom; **Sanne A.E. Peters**, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands, and The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom, and The George Institute for Global Health, University of New South Wales, Sydney, Australia; **Amina Rakisheva**, Cardiology Department, City Cardiology Center, Almaty, Kazakhstan; **Antonia Sambola**, Acute Cardiac Care Unit,

Department of Cardiology, Vall d'Hebron University Hospital, Barcelona, Spain; **Oliver Schlager**, Division of Angiology, Department of Medicine II, Medical University of Vienna, Vienna, Austria; **Florian S. Schoenhoff**, Department of Cardiac Surgery, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland; **Tommaso Simoncini**, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy; **Françoise Steinbach**, ESC Patient Forum, Sophia Antipolis, France; **Isabella Sudano**, Cardiology, University Hospital Zurich University Heart Center, Zurich, Switzerland, and University of Zurich, Switzerland; **Lorna Swan**, Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Glasgow, United Kingdom; **Anne Marie Valente**, Cardiology, Boston Children's Hospital, Boston, MA, United States of America, and Medicine, Brigham and Women's Hospital, Boston, United States of America, MA, and Medicine and Pediatrics, Harvard Medical School, Boston, MA, United States of America.

20. Appendix

ESC Scientific Document Group

Includes Document Reviewers and ESC National Cardiac Societies.

Document Reviewers: Werner Budts (CPG Review Co-ordinator) (Belgium), Karen Sliwa (CPG Review Co-ordinator) (South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa Arbustini (Italy), Giuseppe Boriani (Italy), Antonio Brucato (Italy), Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), Pavel Calda (Czech Republic), G.-Andrei Dan (Romania), Konstantinos Dimopoulos (United Kingdom), Alexandra Frogoudaki (Greece), Estelle Gandjbakhch (France), Eva Gerdtz (Norway), Sofie A Gevaert (Belgium), Bruna Gigante (Sweden), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden), Mark Johnson (United Kingdom), Peter Jüni (United Kingdom), Jolanda Kluin (Netherlands), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Greg Lip (United Kingdom), Emma F. Magavern (United Kingdom), Bill McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), Philip Moons (Belgium), Jens Cosedis Nielsen (Denmark), Ntobeko A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana Potpara (Serbia), Eva Prescott (Denmark), Bianca Rocca (Italy), Jolien Roos-Hesselink (Netherlands), Xavier Rosselló (Spain), Anna Sannino